New combo therapy aims to make inoperable liver cancer removable
NCT ID NCT07075120
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) and focused radiation before surgery in 15 people with advanced liver cancer that is borderline removable. The goal is to see if this approach is safe and can shrink tumors enough to allow complete surgical removal. The study focuses on Native Hawaiian and Pacific Islander patients, who are often underrepresented in research and have higher death rates from this cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab and Nivolumab (immunotherapy drugs) plus stereotactic body radiotherapy (focused radiation)
What this could lead to
If successful, this approach could make surgery possible for more patients with advanced liver cancer and improve survival, especially for underserved populations.
What could go wrong
This is a very early, small pilot study with only 15 participants. The combination of treatments may cause serious side effects, and it is unknown if it will work better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Queen's Medical Center
RECRUITINGHonolulu, Hawaii, 96813, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Hawai'i Cancer Center
NOT_YET_RECRUITINGHonolulu, Hawaii, 96813, United States
Contact
Contact